Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,218,326 shares of the biopharmaceutical company’s stock after selling 52,195 shares during the period. Price T Rowe Associates Inc. MD owned 0.96% of Halozyme Therapeutics worth $58,249,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at $69,000. Retirement Systems of Alabama raised its holdings in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares during the period. Shaker Investments LLC OH raised its holdings in shares of Halozyme Therapeutics by 12.3% during the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock valued at $3,601,000 after buying an additional 8,249 shares during the period. Foster & Motley Inc. raised its holdings in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 12,630 shares during the period. Finally, Jennison Associates LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $731,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $60.57 on Tuesday. The firm has a 50-day moving average price of $60.56 and a 200 day moving average price of $55.20. The firm has a market capitalization of $7.48 billion, a PE ratio of 17.66, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52-week low of $37.97 and a 52-week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,697 shares of company stock worth $1,558,052. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HALO. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.